Search
Hisun Pharmaceutical: Collaborating to Launch Independent Synthetic Biology Venture
2 day ago /
Read about 0 minute
Author：小编
Hisun Pharmaceutical, alongside its wholly-owned subsidiary Hansoh Pharmaceutical's Hong Kong-based arm, Huizheng International, have jointly ventured into the realm of synthetic biology by establishing a new company with a registered capital of 350 million yuan. Hisun Pharmaceutical has contributed 260 million yuan, securing a 74.29% equity stake, while Huizheng International has invested 90 million yuan. This collaboration aims to synergize resources and drive the advancement of synthetic biology enterprises.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
